By targeting surface markers on cancer cells, engineered synthetic receptors expressed on immune cells can be directed to ...

Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical reality.

A recent study led by Associate Professor Takuya Yamamoto and Researcher May Nakajima-Koyama has revealed that maintaining a delicate balance between interferon-gamma (IFN-γ) and extracellular ...

The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 ...

Peptides have emerged as a fascinating class of biomolecules with multifaceted roles across biological systems. Vesugen, a ...

CIRBP Family, Tumors, Molecular Mechanisms, RNA-Binding Proteins, Cellular Stress Share and Cite: Cai, Y. , Wang, T. and Zhan ...

Kuick Research Report Highlights Ongoing Developments In Molecular Switches Application Therapeutic Targets & Drug Delivery ...

In summary, enalapril significantly mitigated multiple pathological markers associated with aging, including lipid droplets, amyloid, glycogen deposition, and fibrosis, in the brain, kidneys, liver, ...

The new study adds to growing evidence that measuring activated proteins is key to cancer therapy selection. Golden, CO, Feb.

Itolizumab demonstrated clinical efficacy after 12 weeks of treatment, achieving a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% ...

Nearly 60,000 people are diagnosed with oral cancer in the U.S. every year, according to the American Cancer Society, and the rate of new cases continues to rise.

Nearly 60,000 people are diagnosed with oral cancer in the U.S. every year, according to the American Cancer Society, and the rate of new cases continues to rise.